Ryan Kaiser, Kaiser IP: Will 2021 be the year the FDA weighs in on CBD?
By Elaine Watson
- Last updated on
Ryan Kaiser, managing partner, Kaiser IP: While I have a personal interest in the clarification of plant-based food products, I expect one subject I (and a lot of others) will be watching is the legal regulated cannabis products, particularly CBD. It will be nice to hopefully get some guidance from FDA to remove some of the uncertainty that comes with marketing CBD products